Abstract
Aim: Malignant bowel obstruction (MBO) in ovarian cancer is poorly understood. Methods: This retrospective cohort study analyzed 129 patients with ovarian cancer and MBO. Results: At presentation, 69 (53%) had platinum-resistant, 37 (29%) platinum-sensitive and 23 (18%) chemotherapy-naive disease. In patients receiving chemotherapy following the MBO episode, median overall survival (OS) was 107 days for chemotherapy-naive patients compared with 83 and 86 for platinum-sensitive or platinum-resistant patients (p = 0.98). OS was inferior for best supportive care (45 days) compared with chemotherapy (152 days) or surgery (124 days; p < 0.001). The Manchester Bowel Obstruction Score using Eastern Cooperative Oncology Group and obstruction level discriminated patients by median OS of 181 days (neither) versus 98 days (one) versus 42 days (both; p < 0.01). Conclusion: The Manchester Bowel Obstruction Score may aide treatment stratification.
Papers of special note have been highlighted as: •• of considerable interest
References
- 1 Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol. Oncol. 96(2), 330–334 (2005).
- 2 . Palliative surgery versus medical management for bowel obstruction in ovarian cancer. Cochrane Database Syst. Rev. (7), CD007792 (2010).
- 3 . Survival time, causes of death, and tumor/treatment-related morbidity in 100 women with ovarian cancer. Hum. Pathol. 19(11), 1273–1279 (1988). •• Highlights the extent of bowel obstruction in ovarian cancer patient. The incidence is likely to be higher than clinically thought.
- 4 . Metastatic patterns in histologic variants of ovarian cancer. An autopsy study. Cancer 64(7), 1508–1513 (1989). •• Highlights the extent of bowel obstruction in ovarian cancer patient. The incidence is likely to be higher than clinically thought.
- 5 . Palliative management of malignant bowel obstruction. Int. J. Gynecol. Cancer 12(2), 135–143 (2002).
- 6 . Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer. J. Support Oncol. 2(4), 323–334; discussion 334–327 (2004).
- 7 Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study. Int. J. Gynecol. Cancer 24(5), 857–864 (2014). •• Highlights the variety and grade of symptoms experienced by ovarian cancer patients in the treatment refractory setting. Provides context for studies in this setting.
- 8 . Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst. Rev. (1), CD002764 (2016).
- 9 Bowel obstruction in elderly ovarian cancer patients: a population-based study. Gynecol. Oncol. 129(1), 107–112 (2013).
- 10 Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC). Gynecol. Oncol. 125(1), 31–36 (2012).
- 11 . Management of bowel obstruction in patients with advanced ovarian cancer. Eur. J. Cancer 30A(11), 1625–1628 (1994).
- 12 . An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer. Int. J. Gynecol. Cancer 16(1), 125–134 (2006). •• Only other studies to look for differences in outcome in malignant bowel obstruction in ovarian carcinomas according to treatment modality, and attempt to define prognostic factors in this setting.
- 13 . Bowel obstruction in patients with ovarian cancer: a search for prognostic factors. Am. J. Obstet. Gynecol. 158(2), 244–249 (1988). •• Only other studies to look for differences in outcome in malignant bowel obstruction in ovarian carcinomas according to treatment modality, and attempt to define prognostic factors in this setting.
- 14 A scoring system for the prognosis and treatment of malignant bowel obstruction. Surgery 152(4), 747–756; discussion 756–747 (2012).
